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Vitamin D receptor (VDR) gene polymorphism was 
studied to find out whether the variants of this gene 
are associated with susceptibility or resistance to 
pulmonary tuberculosis (PTB) and bacteriological  
relapse of tuberculosis. BsmI, ApaI and FokI poly-
morphisms of VDR gene were studied in PTB patients 
(n = 120), patient contacts (spouses of the patients; 
n = 80), bacteriological relapse patients (n = 48) and 
quiescent patients (n = 48). Significant increase of Bb 
genotype (heterozygote carrier) of BsmI polymor-
phism (P = 0.028) and FF  genotype (homozygotes of 
common allele F) of FokI polymorphism (P = 0.034) 
were observed in male PTB patients than male con-
tacts. The BB genotype (homozygote of common allele 
B) of BsmI polymorphism and AA genotype (homo-
zygote of common allele A) of ApaI polymorphism 
were increased in male contacts than male PTB  
patients (BB: P = 0.018; AA: P = 0.04). No significant 
differences were found among female pati nts and 
female contacts. In bacteriological relapse cases of 
PTB, a decreased frequency of AA genotype (P = 
0.015) and an increased frequency of Aa genotype 
(P = 0.024) were observed in bacteriological relapse 
patients than quiescent patients of PTB. The present 
study suggests that Bb genotype of BsmI polymor-
phism and FF  genotype of FokI polymorphism of 
VDR gene may be associated with the susceptibility to 
tuberculosis in males. The BB and AA genotypes may 
be associated with resistance to PTB in males. The 
genotype Aa may be associated with bacteriological 
relapse and AA may be associated with protection 
against bacteriological relapse. 
 
VITAMIN D3 (1,25 dihydroxy vitamin D3), the active form 
of vitamin D regulates calcium and bone metabolism. It 
is an immunoregulatory hormone which plays a vital role 
in monocyte/macrophage activation and is shown to in-
fluence the immune response1. Vitamin D3 is one of the 
few mediators shown to impair the growth of Mycobacte-
rium tuberculosis in the macrophage2. The effects of vita-
min D are exerted by interaction through vitamin D 
receptor (VDR). Various diallelic polymorphisms have 
been identified in the VDR gene (BsmI site – alleles B 
[common allele] and b [infrequent allele]; ApaI site – 
alleles A [common allele] and  [infrequent allele]; TaqI 
sit –alleles T [common allele] and t [infrequent allele]; 
FokI site–alleles F [common allele] and f [infrequent  
allele])3–9. Among these polymorphisms, BsmI and TaqI 
are shown to be associated with the bone mineral den-
sity6,10. The tt genotype of the infrequent allele of TaqI
polymorphism of VDR gene has been shown to be associ-
ated with decreased bone mineral density, resistance to 
primary and secondary hyperthyroidism, and resistance 
to prostatic cancer3,6,7. The variant genotype aa (homo-
zygotes of infrequent allele) of ApaI and bb (homozygote 
of infrequent allele) of BsmI polymorphisms of VDR 
gene have been shown to be associated with increased 
bo mineral density in females10, and the VDR haplo-
types Bat and baT with the regulation of VDR expres-
sion. Moreover, there seems to be no apparent linkage 
disequilibrium between these polymorphis s and the 
VDR FokI polymorphism11. By producing a reporter gene 
construct under the control of a vitamin D response el-
ment, increased vitamin D-dependent transcriptional ac-
tivation of VDR gene was shown with m allele (F allelele 
of FokI polymorphism) than M allele ( f allele of FokI 
polymorphism)12. 
 It has been shown that in the north Indian population, 
tt genotype is associated with tuberculoid leprosy and TT 
genotype with lepromatous leprosy13. The variant geno-
type tt of VDR gene has been shown to be associated with 
decreased risk of tuberculosis in Gambian (African) 
population14. Our recent studies in south Indian pulmo-
nary tuberculosis (PTB)15 and spinal tuberculosis (extra-
pulmonary form of tuberculosis)16 patients revealed that 
variant genotype tt of VDR is associated with susceptibi-
lity to pulmonary as well as spinal tuberculosis in female 
RESEARCH COMMUNICATIONS 
 
CURRENT SCIENCE, VOL. 84, NO. 12, 25 JUNE 2003 1565 
patients; whereas a trend towards an opposite picture 
with the tt genotype was seen in male patients and male 
contacts. We further studied the BsmI, ApaI and FokI 
polymorphisms of VDR gene to find out whether there is 
any association with susceptibility or resistance to PTB 
and bacteriological relapse of PTB. 
 Subjects included in this study were 120 PTB patients, 
and 80 patient contacts (spouses of the patients) as con-
trols. Among the 120 PTB patients, 74 were male and 46 
were female. The mean age with standard error (SE) was 
40.8 ± 1.3 yrs for males and 36.2 ± 1.5 yrs for females. 
Among the 80 control subjects (contacts), 31 were male 
and 49 were female. The mean age with SE was 43.0 ± 
2.3 yrs for males and 36.2 ± 1.2 yrs for females. 
 PTB patients (n= 120) were selected from among sub-
jects of an earlier chemotherapy study, which consisted 
of different drug regimens. Patients classified as suffer-
ing from active PTB (smear and culture positive for  
Mycobacterium tuberculosis) were treated at our centre. 
All these patients had received supervised short course 
chemotherapy for 6 to 8 months duration and had been 
followed up for five years after treatment. During follow-
up, around 10% of the treated patients had a bacteriologi-
cal relapse of the disease. The relapse patients were 
treated with other drug regimens and cured.  
 The relapse and quiescent patients were selected from 
the cured patients (n =120) of the previous chemother-
apy study. Both the relapse and quiescent patients were 
treated/cured 10– 5 years ago. The main criteria for rela-
pse were clinical deterioration and persistent radiograph 
deterioration (chest X-ray). Moreover, two samples of 
sputum were examined by smear and culture monthly up 
to 24 months and three months thereafter. Presence of 
two or more cultures yielding ten or more colonies of M. 
tuberculosis, in different months during a three-month 
period, of monthly follow up or a six-month period, of 
three-month follow-up were taken as evidences of bacte-
riological relapse. The relapse patients were culture-
proven cases. Patients who had a bacteriologi al relapse 
(n = 49) after 6–8 months treatment with short course 
chemotherapy were selected. An equal number of pati-
ents with quiescent disease (n = 49), matched for treat-
ment regimen and duration of follow up were also 
selected. The relapse and quiescent patients were age-
matched. Among the 48 relapses, 39 had occurred in the 
first 12 months of follow-up. Care was taken to select 
quiescent controls who were not related to the patients 
with relapse. The primary treatment regimen consisted of 
rifampicin, isoniazid, pyrazinamide and streptomycin (or 
ethambutol) for the initial phase and two or three drugs in 
the continuation phase for 6–8 months. All the patients 
had bacilli sensitive to streptomycin, isoniazid and rifam-
picin initially. Among the relapse patients, 42 were male 
and 7 were female, aged 41.7 ± 3.2 yrs and 41.1 ± 
11.8 yrs, respectively. Among the quiescent patients, 34 
were male and 15 were female, aged 39.7 ± 3.2 yrs and 
38.3 ± 5.0 yrs, respectively. The relapse patients and the 
quiescent patients were recruited from the same envi-
ronment. They belong to the same socio-economic status 
and the same ethnic origin. 
 Control subjects consisted of spouses of the patients 
(family contacts; n = 80). They were living together with 
the patients, before, during and after treatment. All the 
spouses were clinically normal at the time of blood sam-
ple collection. The patients and the contacts were not 
cons nguineous. They were randomly selected and belon-
ged to the same ethnic origin (Indo-Dravidian descent). 
The pati nts and the spouses were Tamil-speaking South 
Indian population living in and around Chennai, Tamil 
Nadu. 
 DNA was extracted from the peripheral blood white 
cells of patients and control subjects using salting-out 
procedure17. VDR gene polymorphism was studied using 
polymerase chain reaction (PCR) and restriction fragment 
length polymorphism. BsmI, ApaI and FokI polymor-
phism  were studied using the methods described else-
wher8,10. 
 F r BsmI polymorphism, the following primers were 
used to amplify the VDR gene6,10: 5¢ – CAA CCA AGA 
CTA CAA GTA CCG CGT CAG TGA – 3¢; 5¢ – AAC 
CAG CGG GAA GAG GTC AAG GG – 3¢. The PCR cy-
cle conditions were: An initial denaturation step at 94°C 
for 4 min followed by 35 cycles of denaturation at 94°C 
for 30 s, annealing 63°C for 30 s and extension 72°C for 
60 s and finally 2 min extension at 72°C, using 20 mM 
Tris-HCl (pH 8.4), 50 mM KCl, 1 mM MgCl2, 0.4 mM 
dNTPs, 0.01 mM of each primer (Gibco BRL, Grand  
Island, NY, USA), 100 ng of DNA and 1 unit of Taq  
polymerase (Gibco BRL, Grand Island, NY, USA) in a 
25 ml reaction in a programmable thermocycler (MJ Re-
search, Inc., Watertown, MA, USA). The amplified 825 
base-pair (bp) product was subjected to BsmI restriction-
enzyme digestion. Five microlitres of the product was res-
triction digested with 3–5 units of BsmI enzyme (Gibco 
BRL) in a 20 ml reaction at 65°C for 3 h using manufac-
t er’s buffer. The BsmI enzyme-digested product was 
electrophoretically run on a 1.5% agarose gel containing 
0.5 mg/ml ethidium bromide for 45–60 min at 80 V along 
HaeIII digest as marker. Absence of BsmI 
restriction site (825 bp) was assigned as common allele B 
(wild-type allele) and presence of restriction site r sulting 
in 650 bp and 175 bp fragments was assigned as infrequent 
allele b (mutant allele). Genotypes were assigned accord-
ngly as homozygotes for common allele (BB) and homo-
zygotes for infrequent allele (bb). Presence of 825, 650, 
175 bp was assigned as heterozygotes (Bb). 
 For ApaI polymorphism the following primers (Gibco 
BRL) were used to amplify the VDR gene10: 5¢ – CAA 
CCA AGA CTA CAA GTA CCG CGT CAG TGA – 3¢; 
5¢ – CAC TTC GAG CAC AAG GGG CGT TAGC – 3¢. 
The PCR conditions were: Initial denaturation step of 
94°C for 4 min followed by 35 cycles of 94°C for 30 s 
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(denaturation), 65°C for 30 s (annealing) and 72°C  
for 60 s (extension) and a final extension step at 72°C  
for 2 min using 10 mM TAPS [3-Tris(hydroxymethyl) 
methyl aminoprane sulphonic acid], (pH 8.7), 50 mM 
KCl, 1.5 mM MgCl2, 0.01% gelatin (Genei, Bangalore, 
India), 0.6 mM dNTPs, 0.01 mM of each primer, 100ng 
of DNA and 1 unit of Taq polymerase (Gibco BRL) in a 
25 ml reaction and run in a programmable thermocycler 
(MJ Research Inc.). The amplified 2000-bp PCR product 
was subjected to ApaI restriction enzyme (Gibco BRL) 
digestion. Five microlitres of the PCR product was res-
triction digested with 5 units of ApaI restriction enzyme 
in a 20 ml reaction using manuf cturer’s buffer at 30°C 
for 3 h. The ApaI enzyme-digested product was electro-
phoretically (80 V for 1 h) run on a 1.5% agarose gel 
containing 0.5 mg/ml ethidium bromide along with 
HaeIII digest as marker. Absence of ApaI restric-
tion site (2000 bp) was assigned as common allele A 
(wild-type allele) and presence of restriction site result-
ing in 1700 bp and 300 bp fragments was assigned as  
infrequent allele a (mutant allele). Genotypes were as-
signed accordingly as homozygotes for common allele 
(AA) and homozygotes for infrequent allele (a ). Pres-
ence of 2000, 1700 and 300 bp fragments was assigned 
as heterozygotes (Aa). 
 For FokI polymorphism, the following primers were 
used to amplify a 265 bp product from the region flank-
ing exon 2 of VDR gene8: 5¢ – AGC TGG CCC TGG 
CAC TGA CTC TGC TCT – 3¢; 5¢ – ATG GAA ACA 
CCT TGC TTC TTC TCC CTC – 3¢. Next, 100 ng of 
DNA was amplified by PCR using 10 mM Tris HCl, 
50 mM KCl, 1 mM MgCl2, 0.4 mM dNTPs and 1 unit 
Taq DNA polymerase in a 25ml reaction mix. The PCR 
condition involved an initial denaturation of 4 min at 
94°C, followed by 35 cycles of denaturation at 94°C for 
30 s, annealing at 58°C for 30 s and extension at 72°C for 
1 min. A final extension step at 72°C for 2 min was also 
given. The PCR product was verified using a 1% agarose 
gel containing ethidium bromide. The PCR products were 
digested with FokI restriction enzyme at 37°C for 3 h fol-
lowed by electrophoresis in a 2% agarose gel containing 
HaeIII digest was used as the 
molecular weight marker. The FF genotype (homozygote 
of common allele) lacks a FokI site and shows only one 
band of 265 bp. The ff genotype (homozygote of infre-
quent allele) generates two fragments of 196 and 69 bp. 
The heterozygote displays three fragments of 265, 196 
and 69 bp, designated as Ff. 
 The frequencies of the genotypes in the patient groups 
and controls were analysed using 2 with Yates correction 
( 2 ). Wherever an expected cell value was l ss than 5, 
Fisher’s exact test was used. These analyses were carried 
out employing the Statcalc program (Epi Info, Version –
5; USD; Stone Mountain, GA) to find out the statistical 
significance; Odds ratio (OR) and 95% confidential  
interval (CI).  
 No difference in the frequencies of variant genotypes 
of BsmI, ApaI and FokI polymorphisms of VDR gene was 
observed between PTB patients and contacts. However, 
increased trends in the frequencies of Bb genotype of 
BsmI polymorphism and FF genotype of FokI polymor-
phism were observed in total PTB patients than total  
controls. A trend towards a decreased frequ ncy of f 
genotype of FokI polymorphism was seen in total PTB 
patients than controls (Table 1).  
 Since tuberculosis is more prevalent in males18,19, th  
results were further analysed for males and females. In 
PTB, significantly increased frequency of Bb genotype 
(P = 0.028; OR: 3.0; CI: 1.1–8.8) and FF genotype (P = 
 
 
Table 1. Genotype frequencies of BsmI, ApaI and FokI polymor-
phisms of VDR gene in total contacts (spouses), total PTB patients,  
  male and female contacts, and patients
Genotype frequency (%) 
 
 Male Female 
VDR BsmI/ Total Total 
ApaI/FokI  Ct PTB Contacts PTB Contacts PTB 
genotype n = 80 n = 120 n = 31 n = 74 n = 49 n = 46 
 
BsmI 
 BB 40.0 35.0 58.1* 31.5* 28.6 44.4 
 (32) (42) (18) (23) (14) (20) 
 Bb 36.3 46.7 25.8@ 52.1@ 42.9 37.8 
 (29) (56) (8) (38) (21)  (17) 
 bb 23.8 18.3 16.1 17.8 28.6 20.0 
 (19) (22) (5) (13) (14) (9) 
 
ApaI 
 AA 37.5 33.3 51.6£ 28.8£ 28.6 42.2 
 (30) (40) (16) (21) (14) (19) 
 Aa 46.3 47.5 38.7 53.4 51.0 40.0 
 (37) (57) (12) (39) (25) (18) 
 aa 16.3 19.2 9.7 19.2 20.4 20.0 
 (13) (23) (3) (14) (10) (9) 
 
FokI  
 FF 53.8 65.0 38.7$ 63.5$ 61.2 67.4 
 (43) (78) (12) (47) (30) (31) 
 Ff 36.2 30.0 48.4 32.4 30.6 26.1 
 (29) (36) (15) (24) (15)  (12) 
 ff 10.0 5.0 12.9 4.1 8.2 6.5 
  (8) (6) (4) (3) (4) (3) 
Numbers in parentheses represent the subjects positiv  for respective 
genotype. n, subjects studied. 
Ct: Contacts; PTB: Pulmonary tuberculosis; BsmI polymorphism – B: 
Common allele, b: infrequent allele, BB: Homozygote of common  
allele, Bb: Heterozygote carrier, bb: Homozygote of infrequent allele, 
ApaI polymorphism – A: Common allele, a: Infrequent allele, AA:  
Homozygote of common allele, Aa: Heterozygote carrier, aa: Homozy-
gote of infrequent allele, FokI polymorphism – F: Common allele, f: 
Infrequent allele, FF: Homozygote of common allele, Ff: Heterozygote 
carrier, ff: Homozygote of infrequent allele; *BB: Male contacts vs 
male PTB patients; c2y P = 0.018; Odds ratio (OR): 0.33; 95% Confi-
dence Interval (CI): 0.12–0.85; @Bb: Male contacts vs male PTB  
patients; c2y P = 0.028; OR: 3.0; CI: 1.12–8.81; £AA: Male contacts vs 
male PTB patients; c2y P = 0.04; OR: 0.37; CI: 0.1–1.0; $FF: Male con-
tacts vs male PTB patients; c2y P = 0.034; OR: 2.76; CI: 1.07–7.21. 
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Table 2. Association of VDR genotypes with susceptibility or resis ance to PTB 
 Susceptibility Resistance 
 
VDR gene polymorphism Male Female Male Female 
 
BsmI Bb – BB – 
 (Heterozygotes)  (Wild-homozygotes) 
ApaI – – AA – 
   (Wild-homozygotes) 
TaqI TT* tt* – TT* 
 (Wild-homozygotes) (Mutant-homozygotes) – (Wild-homozygotes) 
FokI FF – – – 
 (Wild-homozygotes) 
*Refs 15 and 16. 
 
 
Table 3. Genotype frequency of BsmI, ApaI and FokI polymorphisms  
  of VDR gene in quiescent and relapse patients of PTB 
 Genotype frequency (%) 
 
 PTB patients 
 
VDR-BsmI, ApaI  Quiescent Relapse 
and FokI genotypes  n = 48 n = 48 
 
BsmI BB 41.7 22.9 
  (20) (11) 
  Bb 43.7 62.5 
   (21) (30) 
 bb 14.6 14.6 
  (7) (7) 
ApaI 
 AA 43.7* 18.7* 
  (21) (9) 
 Aa 41.7@ 66.7@ 
  (20) (32) 
 aa 14.6 14.6 
  (7) (7) 
FokI 
 FF 68.8 60.4 
   (33) (29) 
 Ff 25.0 39.6 
  (12) (19) 
 ff 6.2 0 
  (3) (0) 
Failed PCR: One quiescent patient and one relapse patient out of 49 
patients in each group; n, subjects studied; Numbers in parentheses 
represent the subjects positive for respective geno ype; *AA, Quiescent 
patients vs relapse patients; c2y P = 0.015; OR: 0.3; CI: 0.1–0.81; @Aa, 




0.034; OR: 2.76; CI: 1.07–7.21) was observed in male 
patients than male contacts. Whereas, increased fre- 
quency of BB and AA genotypes was observed in male 
contacts than male patients (BB: P = 0.018; OR: 0.33; CI: 
0.12–0.85; AA: P = 0.04; OR: 0.37; CI: 0.1–1.0). A trend 
towards an increased frequency of aa genotype of ApaI 
polymorphism and a decreased frequency of ff genotype 
of FokI polymorphism was observed in male PTB  
patients than male contacts. However, no increase or de-
crease in the BsmI, ApaI and FokI polymorphic vari nts 
of VDR gene was observed in female patients and femal  
contacts (Table 1). An overall picture of various VDR 
gene polymorphisms with susceptibility or resistance to 
PTB is presented in Table 2.  
 In bacteriological relapse patients, significantly de-
creased frequency of AA genotype (P = 0.015; OR: 0.3; 
CI: 0.1–0.81) and an increased frequency of Aa genotype 
(P = 0.024; OR: 2.8; CI: 1.13–6.99) was observed than 
quiescent patients (Table 3). Moreover, trends toward a 
decreased frequency of BB genotype and an increased 
frequency of Bb genotype were also observed in bacterio-
logical relapse patients than quiescent patients (Table 2). 
 The VDR gene polymorphic variants of B mI, ApaI and 
FokI polymorphism of the present study as well as TaqI 
polymorphism of our earlier study15 showed an associa-
tion with the susceptibility or resistance to PTB in South 
Indian patients of Indo-Dravidian descent. However, the 
variant ff genotype of FokI polymorphism of VDR gene 
and 25-hydroxycholecalciferol deficiency have been 
shown to be strongly associated with PTB in Gujarati 
Indians living in London9. Gujarati Indians belong to an 
ethnically different population of Indo-Aryan origin. 
Moreover, the production of vitamin D level may change 
depending on the environment as well as exposure to 
sunlight (ultraviolet rays). In a study carried out in the 
Gambian population (West Africa) PTB patients, the tt 
genotype of TaqI polymorphism of VDR gene was found 
less frequently in cases of PTB, suggesting that this 
genotype may be associated with resistance to PTB, 
whereas ApaI polymorphism showed no assocition14. 
This suggests that the association of variant VDR geno-
types with different ethnic populations may be due to 
gene–environment interaction.  
In the present study, male patients showed an in-
creased frequency of heterozygous genotype Bb f BsmI 
and FF genotype of FokI polymorphisms of VDR gene. 
This suggests that Bb and FF genotypes may be associ-
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ated with the susceptibility to PTB in males. Whereas BB  
and AA genotypes are associated with resistance to PTB 
in male subjects. On the other hand, none of the poly-
morphic variants of the VDR gene studied (BsmI, ApaI, 
FokI) showed any association with the susceptibility or 
resistance toPTB in female subjects. However, our ear-
lier studies showed that the variant genotype tt of TaqI 
polymorphism of VDR gene is associated with the suscp-
tibility to both pulmonary and spinal TB in female pa-
tients15,16. The present study suggests that variant 
genotypes of BsmI, ApaI and FokI sites of VDR gene, ei-
ther alone or in combination with TaqI site of VDR gene, 
may be associated with susceptibility or resistance to 
PTB in males or females. 
 Differential susceptibility with variant genotypes of 
VDR gene in male and female subjects may be due to 
gene–gene interaction. It has been shown that during 
adulthood, rates of TB are consistently higher for men 
than for women18–20. Apart from the exposure to the 
source of infection, one of the mechanisms suggestedfor 
this gender gap is the biological difference20. Further, an 
X-chromosome susceptibility gene has been suggested 
which may contribute to the more number of males with 
tuberculosis observed in many populations21. Moreover, 
besides adrenal and gonadal sex steroids, vitamin D is 
also included in the steroid superfamily. Since the steroid 
hormone receptors share substantial homologies, the sex 
steroid or other steroid hormones may influence VDR 
expression. It has been suggested that a VDR gene effect 
may modulate physiological responses to dietary vitamin 
D and calcium intake as well as the sex hormones as sug-
gested for osteoporosis22, which may play a role in the 
susceptibility or resistance to tuberculosis. Moreover, the 
effect of endogenous and/or intake of vitamin D may 
probably regulate the immunity to tuberculosis in a sus-
ceptible or resistant male or female host.  
 In the present study, while the heterozygote genotypes 
Aa and Bb are associated with the bacteriological relapse 
of PTB, the homozygotes AA and BB of the common  
alleles of ApaI and BsmI are associated with resistance to 
bacteriological relapse. Our earlier study15 revealed the 
association of tt genotype of TaqI polymorphism with  
resistance to bacteriological relapse, irrespective of the 
gender of the patient. Since these genes are strongly 
linked, probably the haplotypes may be associated with 
the regulation of VDR expression. Altered VDR expres-
sion along with other host factors may play a role either 
in the endogenous reactivation or re-i fection.  
 The present study suggests that Bb genotype of BsmI 
polymorphism is associated with susceptibility to PTB in  
males. In females, probably other genotypes such as tt of 
TaqI polymorphism15 may be associated with susceptibi-
lity to PTB. Heterozygote genotypes Aa and Bb may be 
associated with bacteriological relapse of PTB. Due to 
gene–environment and gene–gene interactions, the expre-
ssion of VDR and the action of vitamin D through this 
r ceptor may be modulated. The polymor hic variants of 
VDR gene along with other gene and environmental fac-
tors may be responsible for an altered cell-mediated  
immunity against M. tuberculosis in a susceptible or resi-
stant male or female host.  
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